23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To compare the diagnostic criteria of 2006 (DC 2006) and 2015 (DC 2015) in the Russian population of patients with suspected neuromyelitis optica spectrum disorders (NMOSD), with the calculation of their sensitivity, specificity, accuracy and predictive value. Material and methods. We reviewed medical records of suspected NMOSD patients who were therefore examined for the presence of serum autoantibodies targeting the aquaporin-4 water channel protein (AQP4-IgG) in 6 specialized Russian (Nizhny Novgorod and Moscow) medical centers. One hundred patients (78 female), aged 17 to 74 years (mean 38.1±13.3 years), were included. The follow-up period ranged from 4 to 108 months (mean 59.7±31.6 months). Results. During the follow-up the diagnosis of NMOSD was confirmed in 32 people, and 68 patients had diagnoses different from NMOSD. At the disease onset, 68.8% of patients were seropositive for AQP4-IgG. The mean time for confirming NMOSD diagnosis was 15.2±14.2 months. At the disease onset, 36% of patients fulfilled the DC 2015, the diagnosis was subsequently confirmed in 77.8% out of them. 26% of the patients fulfilled the DC 2006, the diagnosis was subsequently confirmed in 84.6% out of them. The sensitivity of DC 2006/DC 2015 was 69%/88%, specificity 94%/88%, accuracy 86%/88%, negative predictive value 85%/94%, positive predictive value 86%/78%. Conclusion. The specificity, sensitivity and accuracy of modern diagnostic criteria for NMOSD In Russian patients is comparable to those obtained in foreign studies. DC 2015 helps to diagnose NMOSD earlier than DC 2006, but they have a lower specificity.
8 August 2025 in Meditsinskiy sovet = Medical Council
Introduction. The study was driven by the prevalence of secondary progressive multiple sclerosis (SPMS) in Russia and the lack of data on siponimod in the real clinical practice (RCP).Aim. To collect and analyze data on the administration of siponimod in SPMS patients within Russia’s RCP as part of the EMBOSSES study (rEtrospective Multicenter oBservatiOnal Study Siponimod rEal-world Spms).Materials and methods. The study encompassed data of 606 SPMS patients from 11 centers who received siponimod for at least 6 months. The analysed data included demographic and clinical characteristics of patients, changes in the Expanded Disability Status Scale (EDSS) scores over time, percentage of patients with 6-month confirmed disability progression (6mCDP), annualized relapse rate (ARR) for MS, radiological signs of the disease activity and adverse events (AEs).Results. Among the study patients, women predominated (64.9%), while men accounted for 35.1%. The median age of patients was 49.5 (±8.9) years. 143 (23.6%) patients reported relapses during 2 years, whereas relapse-free SPMS was observed in 463 (76.4%) patients. The average EDSS scores remained stable, demonstrating minimal changes from 5.44 (±0.998) to 5.58 (±1.028) scores during the 2-year therapy. The percentage of patients free from 6mCDP was 85.5%. The KaplanMeier analysis revealed that 25% of patients achieved 6mCDP by Month 27 of therapy. The average ARR decreased from 0.14 to 0.032 at 12 months and remained low (0.062) after 2 years of treatment. The MRI showed a decrease in the percentage of patients with Gd+ T1 lesions to their complete absence over 2 years of therapy. Main AEs: lymphopenia, bradycardia, and elevated liver enzymes; serious AEs were observed in 3.3% of all cases.Conclusions. Siponimod demonstrated efficacy in controlling disability progression and inflammatory activity, as well as a favourable safety profile in patients with SPMS in the RCP setting. The results confirm the feasibility of using siponimod in patients with SPMS.
8 August 2025 in Meditsinskiy sovet = Medical Council
Introduction. Over the past 30 years, there has been a dramatic change in approaches to the treatment of multiple sclerosis (MS), due to the development of a large number of drugs with different mechanisms of action for the disease-modifying treatment (DMT) of MS.Aim. To form, based on the analysis of the obtained data, an optimal algorithm for the management of patients with MS receiving cladribine tablets in the conditions of real clinical practice.Materials and methods. A retrospective analysis of the data obtained on the background of therapy with cladribine in MS patients at the end of 2024 was conducted on the basis of the Moscow inter-district departments of MS. The data from outpatient records of MS patients treated with cladribine from 2021 to 2023 were used as research material. Data collection was carried out on the initial clinical and demographic characteristics of patients, as well as indicators of the effectiveness of therapy (average annual frequency of exacerbations, activity according to MRI data and progression according to the EDSS scale) and the presence of adverse reactions against the background of therapy with cladribine.Results. This publication presents the experience of using the drug cladribine in real clinical practice in 267 MS patients in Moscow in the period from 2021 to 2023. Patients who underwent two full annual courses of therapy showed a significant reduction in the mean annual frequency of exacerbations and brain MRI activity after the first year of therapy. There was also no significant increase in neurological deficits according to the EDSS scale. During the safety analysis, good tolerability of the drug was noted. The spectrum of adverse events and their frequency were comparable to the data of the instructions for medical use. Conclusion. Effective treatment of MS patients requires optimizing therapy, balancing benefits and risks, and long-term treatment planning from the moment of diagnosis. All these principles can be met with an understanding of the mechanism of action of the drugs and clear adherence to recommendations for monitoring the duration of washout periods when switching from one MS-modifying drug to another.
23 August 2025 in Neurology, Neuropsychiatry, Psychosomatics
Neuromyelitis optica spectrum disorders (NMOSD, formerly known as opticoneuromyelitis or Devic's disease) are severe chronic autoimmune inflammatory diseases of the central nervous system (CNS) associated with high disability in the absence of adequate treatment. In Russia, no assessment of the medical and social characteristics of this disease and the quality of life of patients has been conducted, which complicates the assessment of the prognosis and the development of medical and social management strategies for these patients.Objective: to analyse the medical and social characteristics and quality of life of patients diagnosed with NMOSD (opticoneuromyelitis).Material and methods. The condition of patients with a confirmed diagnosis of NMOSD or opticoneuromyelitis was assessed using a specially designed questionnaire, which also included questions about patients' attitudes towards their health. The SF-36 international quality of life questionnaire was used to score quality of life. Based on the results of the study, 280 patients diagnosed with NMOSD were surveyed in 21 regions of the Russian Federation.Results. Most patients with NMOSD who are observed by neurologists receive specialised treatment, but half of all patients with NMOSD currently experience some difficulties in obtaining drug therapy. Over the past year, 28.6% of respondents reported an improvement in their health, 39.6% reported no change, and 31.8% reported a deterioration. Self-assessment of health status declines sharply in patients over 55 years of age. The majority (74%) of patients report a decline in vision. Every second patient noted a decrease in vision at the onset of the disease. Severe movement disorders are characteristic, and for the majority (91%) of patients with NMOSD, strenuous physical activities such as running and weight training are not possible. Patients with disability groups I or II are more limited in their physical and mental resources. Patients receiving treatment significantly better assess changes in their health over the past year, both physical and psychological. Those who receive specialized drug therapy have a much better perception of their own health and its prospects. The SF-36 quality of life indices for NMOSD are significantly lower than normal, primarily in terms of physical condition, but also in terms of psychological well-being.Conclusion. In NMOSD, there are pronounced changes in the quality of life of patients, both according to the original questionnaire and according to the SF-36 scale. Receiving timely and adequate treatment significantly improves these indicators and the prognosis.
8 August 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. A nationwide examination of blood relatives of MS patients using free brain MRI for possible detection of RIS and subsequent early diagnosis of MS. Material and methods. In more than 60 regions of the country, relatives of the first degree of kinship (children and siblings) aged 18—50 years of patients with an undisputed diagnosis of MS according to the McDonald criteria in 2017 who were receiving DMTs were called for a free MRI scan of the brain. When focal changes were detected, additional analysis was performed to exclude non-specific vascular changes, migraines, and follow-up was performed for everyone. If RIS was suspected, participants were necessarily referred for inpatient examination to the neurological department No. 2 Federal Medical Center for Brain and Neurotechnology or other large MS centers (by territorial affiliation) for repeated MRI of the brain and spinal cord with contrast, clinical assessment and determination of oligoclonal IgG in cerebrospinal fluid (type of synthesis). Results. For 3 years, information was collected on the results of 416 MRI examinations of healthy first-degree relatives (children and siblings) aged 18—50 years. MRI results. The majority of healthy relatives of the patients (74.6%) showed no focal changes in brain tissue. In 56 examined patients (14.5%), nonspecific or vascular changes were detected that did not imply a demyelinating process. However, 48 people (11.5%) had changes that required additional examination. Only half of them reached the Federal Medical Center and other large centers (the entire survey was proposed to be conducted only within the framework of compulsory medical insurance). Of the 24 patients, 14 were diagnosed with MS and recommended to start treatment urgently. Among the risk factors, it should be noted the transmission of the disease from the mother, the presence of OCI in the CSF, the presence of hypointernative foci on T1-VI, even without accumulation of contrast, as well as the detection of foci in the spinal cord. Conclusion. It is necessary to strengthen monitoring of family members of MS patients in order to take timely measures in case of transition from RIS to MS, without starting the course of infection.
23 August 2025 in Neurology, Neuropsychiatry, Psychosomatics
For a comprehensive study of such a socially significant disease as multiple sclerosis (MS), which occurs predominantly in people of working age and in which neuroinflammation and neurodegeneration go hand in hand, resulting in irreversible damage to the brain and spinal cord, the key point is to decipher the pathophysiological mechanisms of its development and progression. Despite the established relationship between hyperhomocysteinemia and secondary endothelial damage, data on the possible role of homocysteine (Hcy) in disease progression are quite contradictory.Objective: to investigate the informative value of determining the content of markers of oxidative stress, mitochondrial and endothelial dysfunction in patients with MS.Material and methods. The study included 63 patients with MS (40 women, 23 men) aged 35 [30; 43] years. The control group consisted of 43 healthy volunteers (22 men, 21 women) aged 37 [32; 44] years. Depending on the therapy received, patients were divided into two groups: those receiving first-line and second-line therapy; patients receiving natalizumab therapy were considered separately. A neurological examination of patients was performed with an assessment of disease severity using the EDSS scale, and the disease progression index was calculated. The following biomarkers were also determined in the blood of patients and volunteers using enzyme-linked immunosorbent assay: intercellular adhesion molecules (ICAM-1), S-adenosylmethionine, S-adenosylhomocysteine, cysteine, cysteinylglycine, glutathione, and Hcy.Results. A statistically significant correlation was found between disease severity (EDSS disability level) and increased Hcy levels. A statistically significant increase in ICAM-1 levels was also found in patients during periods of disease activity (clinical exacerbation, activity according to MRI data), which allows this molecule to be considered as a biomarker of endothelial dysfunction and inflammation.Conclusion. The results of the study indicate the need to continue studying the pathophysiological causes of the onset and progression of MS, further identifying new biomarkers for predicting the course of MS, and evaluating the effectiveness of drugs that alter the course of MS.